Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown

Background and purpose The COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients’...

Full description

Saved in:
Bibliographic Details
Published in:European journal of neurology Vol. 27; no. 9; pp. 1744 - 1747
Main Authors: Lara, B., Carnes, A., Dakterzada, F., Benitez, I., Piñol‐Ripoll, G.
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01.09.2020
John Wiley and Sons Inc
Subjects:
Aged
Aged, 80 and over
Agitation
Alzheimer Disease - complications
Alzheimer Disease - psychology
Alzheimer's disease
anxiety
Anxiety - complications
Anxiety - psychology
Apathy
Apathy - physiology
Caregivers
Cognitive ability
Confinement
coronavirus
COVID-19
COVID-19 - complications
COVID-19 - psychology
Dementia and Cognitive Disorders
depression
Emotional behavior
Epidemics
Evaluation
Female
Humans
Impact analysis
Male
mild cognitive impairment
Motor activity
Neurodegenerative diseases
Neuropsychological Tests
Pandemics
Psychomotor Agitation - complications
Psychomotor Agitation - psychology
Quality of life
Quality of Life - psychology
Quarantine - psychology
Shelter in place
Short Communication
Signs and symptoms
Spain
Surveys and Questionnaires
Viral diseases
Spain
COVID-19
anxiety
coronavirus
mild cognitive impairment
depression
Alzheimer’s disease
ISSN:1351-5101, 1468-1331, 1468-1331
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Background and purpose The COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients’ neuropsychiatric symptoms and their quality of life after 5 weeks of lockdown in Spain. Methods A total of 40 patients with a diagnosis of MCI (n = 20) or mild AD (n = 20) from the Cognitive Stimulation Program of the Cognitive Disorders Unit were evaluated. All patients had undergone a previous evaluation during the month before the lockdown, and were re‐evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol‐5D questionnaire (EQ‐5D) were used to assess neuropsychiatric symptoms in patients and the quality of life in patients as well in caregivers. Results The mean (SD) total baseline NPI score was 33.75 (22.28), compared with 39.05 (27.96) after confinement (P = 0.028). The most frequently affected neuropsychiatric symptoms were apathy [4.15 (3.78) vs. 5.75 (4.02); P = 0.002] and anxiety [3.95 (3.73) vs. 5.30 (4.01); P = 0.006] in patients with MCI, and apathy [2.35 (2.70) vs. 3.75 (3.78); P = 0.036], agitation [0.45 (1.14) vs. 1.50 (2.66); P = 0.029] and aberrant motor behaviour [1.25 (2.86) vs. 2.00 (2.93); P = 0.044] in patients with AD. We did not observe differences in EQ‐5D scores during the re‐evaluation. The 30% of patients and 40% of caregivers reported a worsening of the patients' health status during confinement. Conclusions The results of this study show the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.
AbstractList The COVID-19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients' neuropsychiatric symptoms and their quality of life after 5 weeks of lockdown in Spain.BACKGROUND AND PURPOSEThe COVID-19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients' neuropsychiatric symptoms and their quality of life after 5 weeks of lockdown in Spain.A total of 40 patients with a diagnosis of MCI (n = 20) or mild AD (n = 20) from the Cognitive Stimulation Program of the Cognitive Disorders Unit were evaluated. All patients had undergone a previous evaluation during the month before the lockdown, and were re-evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol-5D questionnaire (EQ-5D) were used to assess neuropsychiatric symptoms in patients and the quality of life in patients as well in caregivers.METHODSA total of 40 patients with a diagnosis of MCI (n = 20) or mild AD (n = 20) from the Cognitive Stimulation Program of the Cognitive Disorders Unit were evaluated. All patients had undergone a previous evaluation during the month before the lockdown, and were re-evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol-5D questionnaire (EQ-5D) were used to assess neuropsychiatric symptoms in patients and the quality of life in patients as well in caregivers.The mean (SD) total baseline NPI score was 33.75 (22.28), compared with 39.05 (27.96) after confinement (P = 0.028). The most frequently affected neuropsychiatric symptoms were apathy [4.15 (3.78) vs. 5.75 (4.02); P = 0.002] and anxiety [3.95 (3.73) vs. 5.30 (4.01); P = 0.006] in patients with MCI, and apathy [2.35 (2.70) vs. 3.75 (3.78); P = 0.036], agitation [0.45 (1.14) vs. 1.50 (2.66); P = 0.029] and aberrant motor behaviour [1.25 (2.86) vs. 2.00 (2.93); P = 0.044] in patients with AD. We did not observe differences in EQ-5D scores during the re-evaluation. The 30% of patients and 40% of caregivers reported a worsening of the patients' health status during confinement.RESULTSThe mean (SD) total baseline NPI score was 33.75 (22.28), compared with 39.05 (27.96) after confinement (P = 0.028). The most frequently affected neuropsychiatric symptoms were apathy [4.15 (3.78) vs. 5.75 (4.02); P = 0.002] and anxiety [3.95 (3.73) vs. 5.30 (4.01); P = 0.006] in patients with MCI, and apathy [2.35 (2.70) vs. 3.75 (3.78); P = 0.036], agitation [0.45 (1.14) vs. 1.50 (2.66); P = 0.029] and aberrant motor behaviour [1.25 (2.86) vs. 2.00 (2.93); P = 0.044] in patients with AD. We did not observe differences in EQ-5D scores during the re-evaluation. The 30% of patients and 40% of caregivers reported a worsening of the patients' health status during confinement.The results of this study show the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.CONCLUSIONSThe results of this study show the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.
The COVID-19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients' neuropsychiatric symptoms and their quality of life after 5 weeks of lockdown in Spain. A total of 40 patients with a diagnosis of MCI (n = 20) or mild AD (n = 20) from the Cognitive Stimulation Program of the Cognitive Disorders Unit were evaluated. All patients had undergone a previous evaluation during the month before the lockdown, and were re-evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol-5D questionnaire (EQ-5D) were used to assess neuropsychiatric symptoms in patients and the quality of life in patients as well in caregivers. The mean (SD) total baseline NPI score was 33.75 (22.28), compared with 39.05 (27.96) after confinement (P = 0.028). The most frequently affected neuropsychiatric symptoms were apathy [4.15 (3.78) vs. 5.75 (4.02); P = 0.002] and anxiety [3.95 (3.73) vs. 5.30 (4.01); P = 0.006] in patients with MCI, and apathy [2.35 (2.70) vs. 3.75 (3.78); P = 0.036], agitation [0.45 (1.14) vs. 1.50 (2.66); P = 0.029] and aberrant motor behaviour [1.25 (2.86) vs. 2.00 (2.93); P = 0.044] in patients with AD. We did not observe differences in EQ-5D scores during the re-evaluation. The 30% of patients and 40% of caregivers reported a worsening of the patients' health status during confinement. The results of this study show the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.
Background and purpose The COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients’ neuropsychiatric symptoms and their quality of life after 5 weeks of lockdown in Spain. Methods A total of 40 patients with a diagnosis of MCI (n = 20) or mild AD (n = 20) from the Cognitive Stimulation Program of the Cognitive Disorders Unit were evaluated. All patients had undergone a previous evaluation during the month before the lockdown, and were re‐evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol‐5D questionnaire (EQ‐5D) were used to assess neuropsychiatric symptoms in patients and the quality of life in patients as well in caregivers. Results The mean (SD) total baseline NPI score was 33.75 (22.28), compared with 39.05 (27.96) after confinement (P = 0.028). The most frequently affected neuropsychiatric symptoms were apathy [4.15 (3.78) vs. 5.75 (4.02); P = 0.002] and anxiety [3.95 (3.73) vs. 5.30 (4.01); P = 0.006] in patients with MCI, and apathy [2.35 (2.70) vs. 3.75 (3.78); P = 0.036], agitation [0.45 (1.14) vs. 1.50 (2.66); P = 0.029] and aberrant motor behaviour [1.25 (2.86) vs. 2.00 (2.93); P = 0.044] in patients with AD. We did not observe differences in EQ‐5D scores during the re‐evaluation. The 30% of patients and 40% of caregivers reported a worsening of the patients' health status during confinement. Conclusions The results of this study show the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.
Background and purposeThe COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients’ neuropsychiatric symptoms and their quality of life after 5 weeks of lockdown in Spain.MethodsA total of 40 patients with a diagnosis of MCI (n = 20) or mild AD (n = 20) from the Cognitive Stimulation Program of the Cognitive Disorders Unit were evaluated. All patients had undergone a previous evaluation during the month before the lockdown, and were re‐evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol‐5D questionnaire (EQ‐5D) were used to assess neuropsychiatric symptoms in patients and the quality of life in patients as well in caregivers.ResultsThe mean (SD) total baseline NPI score was 33.75 (22.28), compared with 39.05 (27.96) after confinement (P = 0.028). The most frequently affected neuropsychiatric symptoms were apathy [4.15 (3.78) vs. 5.75 (4.02); P = 0.002] and anxiety [3.95 (3.73) vs. 5.30 (4.01); P = 0.006] in patients with MCI, and apathy [2.35 (2.70) vs. 3.75 (3.78); P = 0.036], agitation [0.45 (1.14) vs. 1.50 (2.66); P = 0.029] and aberrant motor behaviour [1.25 (2.86) vs. 2.00 (2.93); P = 0.044] in patients with AD. We did not observe differences in EQ‐5D scores during the re‐evaluation. The 30% of patients and 40% of caregivers reported a worsening of the patients' health status during confinement.ConclusionsThe results of this study show the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.
Author Piñol‐Ripoll, G.
Dakterzada, F.
Carnes, A.
Lara, B.
Benitez, I.
AuthorAffiliation 2 Translational Research in Respiratory Medicine IRBLleida, Hospital Universitari Arnau de Vilanova‐Santa Maria Lleida Spain
1 Unitat Trastorns Cognitius Clinical Neuroscience Research IRBLleida, Santa Maria University Hospital Lleida Spain
AuthorAffiliation_xml – name: 2 Translational Research in Respiratory Medicine IRBLleida, Hospital Universitari Arnau de Vilanova‐Santa Maria Lleida Spain
– name: 1 Unitat Trastorns Cognitius Clinical Neuroscience Research IRBLleida, Santa Maria University Hospital Lleida Spain
Author_xml – sequence: 1
  givenname: B.
  surname: Lara
  fullname: Lara, B.
  organization: IRBLleida, Santa Maria University Hospital
– sequence: 2
  givenname: A.
  surname: Carnes
  fullname: Carnes, A.
  organization: IRBLleida, Santa Maria University Hospital
– sequence: 3
  givenname: F.
  surname: Dakterzada
  fullname: Dakterzada, F.
  organization: IRBLleida, Santa Maria University Hospital
– sequence: 4
  givenname: I.
  surname: Benitez
  fullname: Benitez, I.
  organization: IRBLleida, Hospital Universitari Arnau de Vilanova‐Santa Maria
– sequence: 5
  givenname: G.
  orcidid: 0000-0002-4495-2113
  surname: Piñol‐Ripoll
  fullname: Piñol‐Ripoll, G.
  email: gerard_437302@hotmail.com
  organization: IRBLleida, Santa Maria University Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32449791$$D View this record in MEDLINE/PubMed
BookMark eNp9kctu1TAQhi1URC-w4AWQJTawSOtLYjsbpOpwgEpVu-CytXwcp3Fx7NROOEq76SOw5fX6JLicUkEl8GYszTe__pl_F2z54A0AzzHax_kdGG_2cUlp_Qjs4JKJAlOKt_KfVrioMMLbYDelc4QQ4QQ9AduUlGXNa7wDrk7MFMOQZt1ZNUarYZr7YQx9gso38GJSzo4zDC10tjXQevhxUN6mDg5qtMaPCa7t2MFDd9kZ25t4c_0jwcYmo5KBzRStP4NjZ-Di9MvR25vr77iGLuivTVj7p-Bxq1wyz-7qHvj8bvlp8aE4Pn1_tDg8LnSJRF0oRmpWG6baFq240EIYhCnBnOEGaVVWmq4UrljNGtIQjvMFONbVSiutKtGUdA-82egO06o3jc6uo3JyiLZXcZZBWfl3x9tOnoVvkhNBBeFZ4NWdQAwXk0mj7G3SxjnlTZiSJCViFa-wYBl9-QA9D1P0eb1M0aoignGSqRd_Orq38juXDLzeADqGlKJp7xGM5G3mMmcuf2We2YMHrLZjDifcLmPd_ybW1pn539JyebLcTPwE57fAGg
CitedBy_id crossref_primary_10_3389_fneur_2023_1193768
crossref_primary_10_1007_s11482_025_10427_z
crossref_primary_10_3390_healthcare9121677
crossref_primary_10_1016_j_phrs_2021_105581
crossref_primary_10_17269_s41997_021_00500_z
crossref_primary_10_1002_gps_70100
crossref_primary_10_3233_JAD_200991
crossref_primary_10_3389_fpsyt_2020_585540
crossref_primary_10_1136_bmjopen_2021_053563
crossref_primary_10_3390_brainsci11091165
crossref_primary_10_5812_amh_132868
crossref_primary_10_1007_s10212_024_00850_5
crossref_primary_10_1177_15333175211039089
crossref_primary_10_3233_JAD_215459
crossref_primary_10_1371_journal_pone_0268647
crossref_primary_10_7861_clinmed_2021_0605
crossref_primary_10_3390_ijerph20115918
crossref_primary_10_3389_fmed_2024_1388767
crossref_primary_10_3389_fpsyt_2020_578628
crossref_primary_10_1016_j_cger_2022_03_002
crossref_primary_10_1055_a_1548_4602
crossref_primary_10_1007_s00415_020_10070_8
crossref_primary_10_1007_s12144_023_05601_1
crossref_primary_10_1016_j_jad_2020_12_057
crossref_primary_10_1080_10833196_2025_2496862
crossref_primary_10_1177_25424823251377732
crossref_primary_10_7189_jogh_13_06045
crossref_primary_10_1155_jare_9924448
crossref_primary_10_1016_j_physbeh_2021_113392
crossref_primary_10_3233_JAD_201580
crossref_primary_10_2196_29210
crossref_primary_10_1111_ene_14741
crossref_primary_10_3390_jpm11080746
crossref_primary_10_3389_fpsyt_2022_879598
crossref_primary_10_1155_2022_3012778
crossref_primary_10_1093_ndt_gfac008
crossref_primary_10_1017_neu_2022_7
crossref_primary_10_1186_s12877_024_05563_4
crossref_primary_10_1007_s00415_023_11899_5
crossref_primary_10_1007_s44202_024_00204_8
crossref_primary_10_3390_su15086608
crossref_primary_10_3233_JAD_220887
crossref_primary_10_1177_08982643231223555
crossref_primary_10_1007_s10072_021_05231_0
crossref_primary_10_3389_fnagi_2020_588872
crossref_primary_10_3389_fpsyt_2021_590104
crossref_primary_10_3389_fnagi_2021_762907
crossref_primary_10_1007_s40520_021_01911_1
crossref_primary_10_3389_fpsyt_2021_711658
crossref_primary_10_1007_s10072_020_04902_8
crossref_primary_10_1002_mus_27378
crossref_primary_10_3233_JAD_210335
crossref_primary_10_1177_14713012211059021
crossref_primary_10_1186_s12883_024_03975_8
crossref_primary_10_1016_j_arr_2021_101406
crossref_primary_10_1186_s12889_021_11414_3
crossref_primary_10_1080_13607863_2022_2084509
crossref_primary_10_1111_psyg_70081
crossref_primary_10_3233_JAD_215095
crossref_primary_10_7759_cureus_66942
crossref_primary_10_2196_26474
crossref_primary_10_1186_s12877_021_02257_z
crossref_primary_10_1186_s12877_022_02824_y
crossref_primary_10_3389_fpsyt_2020_590134
crossref_primary_10_1007_s11606_021_06674_z
crossref_primary_10_14746_quageo_2022_0043
crossref_primary_10_1177_15333175211072387
crossref_primary_10_1186_s12877_024_04708_9
crossref_primary_10_2196_30598
crossref_primary_10_1111_ene_14373
crossref_primary_10_1024_1662_9647_a000329
crossref_primary_10_12688_hrbopenres_14202_1
crossref_primary_10_3390_ijerph17249419
crossref_primary_10_1111_ijcp_13746
crossref_primary_10_1002_gps_5708
crossref_primary_10_1111_psyg_12810
crossref_primary_10_1080_07317115_2021_1928356
crossref_primary_10_1177_14713012211053971
crossref_primary_10_3233_JAD_210079
crossref_primary_10_1002_trc2_12236
crossref_primary_10_3389_fpsyt_2020_578672
crossref_primary_10_3389_fpsyt_2020_579842
crossref_primary_10_1177_1533317520976720
crossref_primary_10_1007_s11136_021_03056_0
crossref_primary_10_1016_j_bbih_2020_100177
crossref_primary_10_3390_ijerph19159573
crossref_primary_10_3389_fpsyt_2022_826371
crossref_primary_10_1002_gps_5567
crossref_primary_10_1007_s40620_021_01005_1
crossref_primary_10_1038_s41598_022_05687_w
crossref_primary_10_3233_JAD_220221
crossref_primary_10_3389_fnagi_2021_652833
crossref_primary_10_3389_fpsyt_2024_1340498
crossref_primary_10_1007_s40120_024_00676_9
crossref_primary_10_1080_13607863_2021_1958145
crossref_primary_10_3389_fneur_2020_589901
crossref_primary_10_3390_brainsci12101405
crossref_primary_10_7759_cureus_19934
crossref_primary_10_3389_fpsyt_2022_849808
crossref_primary_10_5093_clh2025a11
crossref_primary_10_1002_gps_5693
crossref_primary_10_3389_fnagi_2021_827273
crossref_primary_10_3390_ijerph192315511
crossref_primary_10_3390_jpm13091410
crossref_primary_10_1515_revneuro_2020_0074
crossref_primary_10_3233_JAD_201396
crossref_primary_10_1002_gps_5610
crossref_primary_10_3233_JAD_201430
crossref_primary_10_3389_fpsyt_2022_995308
crossref_primary_10_1186_s12877_022_03379_8
crossref_primary_10_3390_ijerph18158120
crossref_primary_10_1024_1662_9647_a000273
crossref_primary_10_1038_s41598_025_95051_5
crossref_primary_10_3389_fpsyt_2022_839683
crossref_primary_10_3389_fpsyt_2020_599851
crossref_primary_10_3389_fpsyt_2020_578015
Cites_doi 10.1212/WNL.44.12.2308
10.1016/S0140-6736(20)30755-8
10.1002/jmv.25678
10.1111/jgs.16472
10.1016/j.jalz.2011.03.008
10.1016/j.jalz.2011.03.005
10.47102/annals-acadmedsg.202043
10.3390/ijerph17082690
ContentType Journal Article
Copyright 2020 European Academy of Neurology
2020 European Academy of Neurology.
Copyright © 2020 European Academy of Neurology
Copyright_xml – notice: 2020 European Academy of Neurology
– notice: 2020 European Academy of Neurology.
– notice: Copyright © 2020 European Academy of Neurology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
C1K
K9.
7X8
5PM
DOI 10.1111/ene.14339
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Toxicology Abstracts
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate COVID‐19 and Alzheimer’s disease
EISSN 1468-1331
EndPage 1747
ExternalDocumentID PMC7283827
32449791
10_1111_ene_14339
ENE14339
Genre shortCommunication
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Spain
GeographicLocations_xml – name: Spain
GrantInformation_xml – fundername: Department of Health Catalonia Coverment (PERIS)
  funderid: SLT008/18/00050
– fundername: Agència de Gestió d'Ajuts Universitaris i de Recerca
  funderid: FI_B100153
– fundername: Department of Health Catalonia Coverment (PERIS)
  grantid: SLT008/18/00050
– fundername: Agència de Gestió d'Ajuts Universitaris i de Recerca
  grantid: FI_B100153
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
169
1OB
1OC
24P
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
8FI
8FJ
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIVO
ABJNI
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCMX
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADPDF
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFGKR
AFKRA
AFPWT
AFRAH
AFWVQ
AFZJQ
AHMBA
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F5P
FEDTE
FUBAC
FYBCS
FYUFA
G-S
G.N
GODZA
H.X
HF~
HMCUK
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
OVEED
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIG
RIWAO
RJQFR
ROL
RPM
RX1
SAMSI
SUPJJ
TEORI
UB1
UKHRP
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AGQPQ
AGXDD
AIDQK
AIDYY
AIQQE
CITATION
GROUPED_DOAJ
O8X
PHGZM
WIN
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
C1K
K9.
7X8
5PM
ID FETCH-LOGICAL-c4089-a62969e6aff0b78c88e01321761d0ca45c3ba15696d2d27114671c5bcaca58d43
IEDL.DBID WIN
ISICitedReferencesCount 140
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000542383600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1351-5101
1468-1331
IngestDate Tue Nov 04 02:00:30 EST 2025
Sun Nov 09 14:10:11 EST 2025
Sat Nov 29 14:52:23 EST 2025
Wed Feb 19 02:29:07 EST 2025
Sat Nov 29 05:12:47 EST 2025
Tue Nov 18 22:39:05 EST 2025
Wed Jan 22 16:34:08 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords COVID-19
anxiety
coronavirus
mild cognitive impairment
depression
Alzheimer’s disease
Language English
License 2020 European Academy of Neurology.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4089-a62969e6aff0b78c88e01321761d0ca45c3ba15696d2d27114671c5bcaca58d43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-4495-2113
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7283827
PMID 32449791
PQID 2435528672
PQPubID 1066358
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7283827
proquest_miscellaneous_2406575186
proquest_journals_2435528672
pubmed_primary_32449791
crossref_primary_10_1111_ene_14339
crossref_citationtrail_10_1111_ene_14339
wiley_primary_10_1111_ene_14339_ENE14339
PublicationCentury 2000
PublicationDate September 2020
PublicationDateYYYYMMDD 2020-09-01
PublicationDate_xml – month: 09
  year: 2020
  text: September 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
– name: Hoboken
PublicationTitle European journal of neurology
PublicationTitleAlternate Eur J Neurol
PublicationYear 2020
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2020; 17
1994; 44
2020; 49
2020; 68
1999; 112
2020
2020; 395
2020; 92
2011; 7
e_1_2_8_13_1
e_1_2_8_14_1
e_1_2_8_15_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
Badia X (e_1_2_8_9_1) 1999; 112
e_1_2_8_8_1
e_1_2_8_10_1
e_1_2_8_12_1
Troyer EA (e_1_2_8_11_1) 2020
32492256 - Eur J Neurol. 2020 Sep;27(9):1742-1743
References_xml – volume: 44
  start-page: 2308
  year: 1994
  end-page: 2314
  article-title: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia
  publication-title: Neurology
– start-page: S0889‐1591(20)30489‐X
  year: 2020
  article-title: Are we facing a crashing wave of neuropsychiatric sequelae of COVID‐19? Neuropsychiatric symptoms and potential immunologic mechanisms
  publication-title: Bran Behav Immun
– volume: 395
  start-page: 1190
  year: 2020
  end-page: 1191
  article-title: Dementia care during COVID‐19
  publication-title: Lancet
– volume: 7
  start-page: 263
  year: 2011
  end-page: 269
  article-title: The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
  publication-title: Alzheimers Dement
– volume: 112
  start-page: 79
  issue: Suppl. 1
  year: 1999
  end-page: 86
  article-title: The Spanish Version of EuroQol: a description and its applications. European Quality of Life Scale
  publication-title: Med Clin (Barc)
– volume: 49
  start-page: 155
  year: 2020
  end-page: 160
  article-title: Mental health strategies to combat the psychological impact of COVID‐19 beyond paranoia and panic
  publication-title: Ann Acad Med Singapore
– volume: 17
  year: 2020
  article-title: Coronavirus Diseases (COVID‐19) current status and future perspectives: a narrative review
  publication-title: Int J Environ Res Public Health
– volume: 68
  start-page: 926
  year: 2020
  end-page: 929
  article-title: COVID‐19 and older adults: what we know
  publication-title: J Am Geriatr Soc
– volume: 7
  start-page: 270
  year: 2011
  end-page: 279
  article-title: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
  publication-title: Alzheimers Dement
– volume: 92
  start-page: 401
  year: 2020
  end-page: 402
  article-title: Outbreak of pneumonia of unknown etiology in Wuhan, China: the mistery and the miracle
  publication-title: J Med Virol
– ident: e_1_2_8_10_1
  doi: 10.1212/WNL.44.12.2308
– ident: e_1_2_8_14_1
– start-page: S0889‐1591(20)3
  year: 2020
  ident: e_1_2_8_11_1
  article-title: Are we facing a crashing wave of neuropsychiatric sequelae of COVID‐19? Neuropsychiatric symptoms and potential immunologic mechanisms
  publication-title: Bran Behav Immun
– ident: e_1_2_8_13_1
  doi: 10.1016/S0140-6736(20)30755-8
– ident: e_1_2_8_3_1
– ident: e_1_2_8_2_1
  doi: 10.1002/jmv.25678
– ident: e_1_2_8_15_1
– ident: e_1_2_8_6_1
  doi: 10.1111/jgs.16472
– ident: e_1_2_8_7_1
  doi: 10.1016/j.jalz.2011.03.008
– volume: 112
  start-page: 79
  issue: 1
  year: 1999
  ident: e_1_2_8_9_1
  article-title: The Spanish Version of EuroQol: a description and its applications. European Quality of Life Scale
  publication-title: Med Clin (Barc)
– ident: e_1_2_8_4_1
– ident: e_1_2_8_8_1
  doi: 10.1016/j.jalz.2011.03.005
– ident: e_1_2_8_12_1
  doi: 10.47102/annals-acadmedsg.202043
– ident: e_1_2_8_5_1
  doi: 10.3390/ijerph17082690
– reference: 32492256 - Eur J Neurol. 2020 Sep;27(9):1742-1743
SSID ssj0002720
Score 2.6345167
Snippet Background and purpose The COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild...
The COVID-19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) are...
Background and purposeThe COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1744
SubjectTerms Aged
Aged, 80 and over
Agitation
Alzheimer Disease - complications
Alzheimer Disease - psychology
Alzheimer's disease
anxiety
Anxiety - complications
Anxiety - psychology
Apathy
Apathy - physiology
Caregivers
Cognitive ability
Confinement
coronavirus
COVID-19
COVID-19 - complications
COVID-19 - psychology
Dementia and Cognitive Disorders
depression
Emotional behavior
Epidemics
Evaluation
Female
Humans
Impact analysis
Male
mild cognitive impairment
Motor activity
Neurodegenerative diseases
Neuropsychological Tests
Pandemics
Psychomotor Agitation - complications
Psychomotor Agitation - psychology
Quality of life
Quality of Life - psychology
Quarantine - psychology
Shelter in place
Short Communication
Signs and symptoms
Spain
Surveys and Questionnaires
Viral diseases
Title Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fene.14339
https://www.ncbi.nlm.nih.gov/pubmed/32449791
https://www.proquest.com/docview/2435528672
https://www.proquest.com/docview/2406575186
https://pubmed.ncbi.nlm.nih.gov/PMC7283827
Volume 27
WOSCitedRecordID wos000542383600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Free Content
  customDbUrl:
  eissn: 1468-1331
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002720
  issn: 1351-5101
  databaseCode: WIN
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1468-1331
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002720
  issn: 1351-5101
  databaseCode: DRFUL
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Pb9MwFH8aY0JcgAGDwKg8tAOXSLXjxLY4TVsrJkE3wTZ6ixzbUSPaZGo60OCyj8CVr7dPgu2k0aqBhMQtkl8Ux37_7Pfe7wHsaqpyZ3bssSRjIc0TYWUucoCXmhjCjaZG-WYTbDTi47E4XoO3y1qYBh-iu3BzkuH1tRNwmdU3hNyqAivmUeSK9zDFrnvB58NRp4VdfNEftmIcOr5rUYVcFk_35qotuuVg3s6TvOm_egM0fPhfU38ED1q_E-01jLIJa6Z8DPc-tJH1J_DDo3R0uc-FQvXl7HxRzWokS42a2stLVOVoWuQGFSX6ZPVIUU9Qi8xaI3eli_am3yemmJn59dWvGrXhH9QUQyLrbKL9o7PDg-urn1gga0e_6Opb-RROh4OT_Xdh25ghVLTPRSgTIhJhEpnn_YxxxblxIRvMEqz7StJYRZm0B0ORaKIJc4XPDKs4U1LJmGsabcF6WZXmOaCIE4XjjEgsODVcS5kLKg1nWuooj1UAb5ZblKoWtdw1z5imy9OLXczUL2YArzvS8waq409E28t9TltprVNifcaY8ISRAHa6YStnLngiS1NdOJp-E6NKAnjWsEX3FeuUUsEEDoCtMExH4DC8V0fKYuKxvJl17zhh9jc9w_x94ulgNPAPL_6d9CXcJ-56wKfEbcP6Yn5hXsGG-roo6nkP7rAx78Hdg4_D0_c9Lz2_AVQFHok
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NTtwwEB5RWrVcSn8hhRa36qGXSBvHiW2pFwSLWBVCpdKWW-TYjjbqboI2Cwh64RG48no8CbaTjVjRSpV6i-SJ4tgz9jczns8AHxWRud12jFuSUZ_kMTc2F1rCS4U1ZloRLd1lEzRJ2NER_7oAn2e1MA0_RBdws5bh1mtr4DYgfcfKzVpg7DwM-QN4SAzQsBc3_Bwk3TpsM4zO3YoC32peyytkz_F0r87vRvcg5v2TkncRrNuCdpb_r_PP4GkLPdFmoyvPYUGXL-Dxfptcfwm_HVFHd_y5kKg-Hx9Pq3GNRKlQU355jqocjYpco6JE38xSUtRD1JKz1shGddHm6GKoi7Ge3Fxe16jNAKGmHhIZvIm2Dn4Mtm8urwKOzFb6S1Vn5Sv4vtM_3Nr127sZfEl6jPsixjzmOhZ53ssok4xpm7UJaByonhQkkmEmjG_IY4UVprb2mQYyyqSQImKKhK9hsaxKvQooZFgGUYZFwBnRTAmRcyI0o0qoMI-kB59mc5TKlrjc3p8xSmcOjBnM1A2mBx860eOGreNPQuuziU5bg61TbGBjhFlMsQfvu2ZjajZ_IkpdnViZXpOmij1YafSi-4rBpYRTHnhA5zSmE7A03vMtZTF0dN7UIDyGqflNpzF_73jaT_ru4c2_i27Ak93D_b10b5B8WYMlbKMF7oTcOixOJyf6LTySp9OinrxzxnMLWtIgHw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Pb9MwFH8aHZq4MP4NwgYYxIFLpMZxYlviMq2tmBhlAoZ2ixzbUSPapGo60OCyj8CVr7dPgu240aqBhMQtkl8Ux37_7Pfe7wG8VEQW1uyYY0lOQ1Kk3MhcbAEvFdaYaUW0dM0m6HjMTk_58Qa8XtXCtPgQ3YWblQynr62A67kqrki50QVGzuOY34BNYpvI9GBz8GF0ctRpYhtjdAeuJAot73lkIZvJ0728bo-uOZnXcyWv-rDOCI22_2_6d-C2dz7Rfsstd2FDV_dg650Pr9-HHw6qo0uALiVqzmfzZT1rkKgUagswz1FdoGlZaFRW6KNRJmUzQR6etUH2XhftT79PdDnTi8uLXw3yMSDUVkQi43Gig_efDweXFz8jjowx_aLqb9UDOBkNPx28CX13hlCSPuOhSDFPuU5FUfRzyiRj2sZtIppGqi8FSWScC3M65KnCClNb_UwjmeRSSJEwReId6FV1pR8BihmWUZJjEXFGNFNCFJwIzagSKi4SGcCr1R5l0kOX2w4a02x1hDGLmbnFDOBFRzpv8Tr-RLS32ujMi2yTYeM4JpilFAfwvBs2wmYjKKLS9Zml6beBqjSAhy1fdF8xninhlEcB0DWO6QgskPf6SFVOHKA3NT4ew9T8puOYv088G46H7uHxv5M-g63jwSg7Ohy_3YVb2F4XuBS5PegtF2f6CdyUX5dls3jqpec3PPsgyA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuropsychiatric+symptoms+and+quality+of+life+in+Spanish+patients+with+Alzheimer%27s+disease+during+the+COVID-19+lockdown&rft.jtitle=European+journal+of+neurology&rft.au=Lara%2C+B&rft.au=Carnes%2C+A&rft.au=Dakterzada%2C+F&rft.au=Benitez%2C+I&rft.date=2020-09-01&rft.eissn=1468-1331&rft.volume=27&rft.issue=9&rft.spage=1744&rft_id=info:doi/10.1111%2Fene.14339&rft_id=info%3Apmid%2F32449791&rft.externalDocID=32449791
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-5101&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-5101&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-5101&client=summon